Back |
home / stock / apre / apre message board
Subject | By | Source | When |
---|---|---|---|
It's good to know they are still a | RockStarInvestor | investorshub | 01/13/2021 2:29:20 PM |
A higher price at closing charts some positive | RockStarInvestor | investorshub | 01/12/2021 5:29:35 AM |
I am hoping with the conference tomorrow that | RockStarInvestor | investorshub | 01/11/2021 3:27:20 PM |
Premarket is up. I hope it will continue | RockStarInvestor | investorshub | 01/11/2021 2:18:13 PM |
Yeah. I agree. This one attempt has allowed | RockStarInvestor | investorshub | 01/10/2021 11:35:18 PM |
Yes--I think we are on the right track | EF5$tocks | investorshub | 01/10/2021 11:01:17 PM |
I hope that others will find value as | RockStarInvestor | investorshub | 01/10/2021 8:52:15 PM |
Your my 1st message! Yeah I agree. Oversold | RockStarInvestor | investorshub | 01/10/2021 6:17:41 PM |
Hi RockStar, in $APRE at an average of | EF5$tocks | investorshub | 01/09/2021 9:45:31 PM |
Welcome! Just started this board. I am hoping | RockStarInvestor | investorshub | 01/09/2021 4:20:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NYSE Market:
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data in 2H 2024 Through the first 5 cohorts, ATRN-119 has been fo...
2024-05-16 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation in ABOYA-119 c...